Xeris puts financing in place for redemption of 5% convertibles due 2025

Chicago, March 6 – Xeris Biopharma Holdings, Inc. announced it has a financing strategy in place for the redemption of its remaining 5% convertible senior notes due 2025.

The company borrowed $200 million in the form of a term loan from Hayfin Capital.

The loan may be expanded by $15.2 million to cover the redemption of the convertible notes due mid-2025, if needed.

The Chicago-based specialty pharmaceutical company develops and commercialize ready-to-use injectable and infusible drug formulations.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.